Insider buying last 90 days
$493Kin 2 open-market purchases
| Filed | Insider | Type | Value |
|---|---|---|---|
| Aug 18 | BIENAIME JEAN JACQUES director | Purchase | $270K |
| Aug 18 | BIENAIME JEAN JACQUES director | Purchase | $222K |
From Form 4 filings, dated to when each was filed.
Ascendis Pharma enters the week ahead of its third quarter 2026 results, scheduled for release on 12 November 2026 before the U.S. market open. The announcement itself carries no operational detail, but it sets the stage for the company's next update on its TransCon portfolio, which includes SKYTROFA, YORVIPATH and YUVIWEL.
ASND closed at $259.85, up 1.2%, sitting above both its 50-day average of $242.74 and its 200-day average of $239.15, with the 50-day above the 200-day. The GekkoIndex reads 46.8, placing the stock in the Neutral zone, down 4.1 over five sessions. Shares trade about 2.9% below Gekko Fair Value of $267.70, within the 52-week range of $188.07 to $282.15.
The next earnings date, 12 November 2026, falls inside the coming 20-trading-day window and carries an average absolute reaction of 4.3% based on history; the last report beat estimates ($3.29 versus $1.71) yet the stock reacted -2.7%. Over the last 90 days, insiders made 2 open-market purchases totaling $492,654. Analyst coverage from 19 firms stands at 18 buy and 1 hold ratings, with a consensus target of $305.73, implying 17.7% upside. Seasonally, the next 20 trading days have averaged +0.7% over 5 years, rising in 3 of them.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
Ascendis Pharma scores 4 supportive, 1 mixed and 1 headwind across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive1 mixed1 headwind
Above 50 and 200-day
Close $275.39 is above the 50-day ($242.67) and 200-day ($239.85) averages, and the 50-day is above the 200-day.
See the chart42.9, Distribution
Reading 42.9 is in the Distribution zone.
See the GekkoIndex2.7% above
Price is within 5% of Gekko Fair Value (2.7% above).
See fair valueLeans bullish
Last 90 days: 2 open-market insider purchases.
See smart moneyReports in 87 days
Next report Feb 10, 2027, 87 days away — outside a typical 20-trading-day hold.
See earnings+6.6% on average
From this point in the calendar, the next 20 trading days averaged +6.6% over 5 years, rising in 4 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Ascendis Pharma closed at $275.39 on Nov 13, 2026, +38.2% over the past year, inside a 52-week range of $188.07 to $282.15.
Use the left and right arrow keys to read daily values.
Put ASND on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Ascendis Pharma develops medical treatments aimed at serious conditions where existing options remain limited. Its approved product, SKYTROFA, treats growth hormone deficiency. Beyond this, the company is best known for its work using TransCon technology to build a broader pipeline of experimental therapies.
That pipeline includes a growth hormone candidate being studied for pediatric patients in Japan and for adults with the same deficiency, along with a parathyroid hormone treatment for adults with hypoparathyroidism and a compound targeting pediatric achondroplasia. The company is also working on a therapy delivered directly into tumors using a toll-like receptor agonist, and a separate treatment designed for systemic delivery based on interleukin-2 biology. Together these programs form the core of how Ascendis Pharma builds out its treatment offerings beyond its marketed product.
The company was established in 2006 and is headquartered in Hellerup, Denmark. Its shares trade under the ticker ASND.
Ascendis Pharma’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 42.9, in the Distribution zone, down 5.1 points over five sessions.
Down 5.1 points over five sessions, from the Neutral zone.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 16 | +11.1% | +12.5% | ||
| Accumulation | 189 | +2.2% | +6.3% | ||
| Neutral | 432 | −0.5% | −0.2% | ||
| Distribution (current zone) | 18 | +0.1% | −2.2% | ||
| Selling | 0 | Not available | |||
Average ASND share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Distribution readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Distribution zone: Institutions potentially offloading. About the five zones →
Ascendis Pharma trades 2.7% above Gekko Fair Value of $268.25, so the shares are about fair value on Gekko’s estimate.
Gekko’s own estimate of what Ascendis Pharma shares are worth, recalculated every trading day.
$268.25
Gekko Fair Value, Nov 14, 2026
2.7% above fair value · About fair value
At the end of Aug 2026 the price was 10.5% below the estimate.
Insiders filed 2 open-market purchases in Ascendis Pharma worth $493K, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
$493Kin 2 open-market purchases
| Filed | Insider | Type | Value |
|---|---|---|---|
| Aug 18 | BIENAIME JEAN JACQUES director | Purchase | $270K |
| Aug 18 | BIENAIME JEAN JACQUES director | Purchase | $222K |
From Form 4 filings, dated to when each was filed.
No trades in ASND were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
0of the funds Gekko tracks hold ASND.
Ascendis Pharma reports on Feb 10, 2027, after the close (87 days away), and beat the EPS estimate in 4 of its last 8 reports.
Feb 10, 2027
Expected after the close, 87 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Nov 12, 2026 | $1.24 est $0.92 | $418.8M est $409.4M | +6.2% |
| Aug 13, 2026 | $3.29 est $1.71 | $387.5M est $376.8M | −2.7% |
| May 7, 2026 | $0.27 est $0.43 | $284.9M est $308.9M | +1.2% |
| Feb 11, 2026 | −$0.55 est −$0.24 | $344.8M est $292.3M | −2.7% |
| Nov 12, 2025 | −$1.00 est −$0.12 | $250.2M est $302.6M | +2.6% |
| Aug 7, 2025 | −$0.93 est −$1.42 | $186.1M est $233.1M | +4.9% |
| May 1, 2025 | −$1.58 est −$1.51 | $110.7M est $153.5M | +1.0% |
| Feb 12, 2025 | −$0.64 est −$1.17 | $180.1M est $125.4M | +19.2% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Ascendis Pharma is $306.63, +11.3% from the last close, from 21 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 21 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 13 | Wells Fargo | $330 | +19.8% |
| Nov 13 | Wedbush | $346 | +25.6% |
| Nov 13 | UBS | $315 | +14.4% |
| Nov 13 | TD Cowen | $352 | +27.8% |
| Nov 13 | Morgan Stanley | $302 | +9.7% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, Ascendis Pharma averaged +6.6% across the last 5 years, rising in 4 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | 0.0% | 2 of 5 |
| Next 10 trading days | +2.1% | 4 of 5 |
| Next 15 trading days | +4.3% | 4 of 5 |
| Next 20 trading days | +6.6% | 4 of 5 |
| Next 30 trading days | +7.8% | 4 of 5 |
For scale, ASND’s typical 20-trading-day move in either direction is about 6%.
Ascendis Pharma’s market cap is $18.06B, with a P/E ratio of 18.2 and revenue of $1.20B over the last twelve months.
Coverage of Ascendis Pharma this week reads positive: 7 positive, 3 neutral and 0 negative headlines.
Ascendis Pharma’s market cap is $18.06B at the Nov 13, 2026 close of $275.39, with 65.60M shares outstanding. The shares trade on a P/E ratio of 18.2.
The consensus analyst 12-month price target for Ascendis Pharma is $306.63, +11.3% from the last close. Of the 21 firms that rated the stock in the last 90 days, 20 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Ascendis Pharma is about fair value: the Nov 13, 2026 close of $275.39 is 2.7% above Gekko Fair Value of $268.25. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Ascendis Pharma is expected to report on Feb 10, 2027, after the market closes (87 days away). Analysts expect earnings of $1.40 per share on revenue of $507.8M. Ascendis Pharma beat the earnings estimate in 4 of its last 8 reports, moving 5.1% on average across the report.
Ascendis Pharma’s 52-week high is $282.15 and its 52-week low is $188.07; it closed at $275.39 on Nov 13, 2026, +38.2% over the past year.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 6 items with data read as supportive (trend, smart money, earnings risk and seasonality), 1 as mixed (fair value) and 1 as a headwind (gekkoindex). The checklist is a description of current data, not a recommendation.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.